Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Monoclonal BRCA1 Primary Antibody for ChIP, ICC - ABIN450350
Arizti, Fang, Park, Yin, Solomon, Ouchi, Aaronson, Lee: Tumor suppressor p53 is required to modulate BRCA1 expression. in Molecular and cellular biology 2000
Show all 9 Pubmed References
Human Monoclonal BRCA1 Primary Antibody for IHC (p), IP - ABIN445490
Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001
Show all 8 Pubmed References
Human Polyclonal BRCA1 Primary Antibody for FACS, WB - ABIN151683
Zaugg, Su, Reilly, Moolani, Cheung, Hakem, Hirao, Liu, Elledge, Mak: Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. in Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 7 Pubmed References
Human Polyclonal BRCA1 Primary Antibody for IHC - ABIN965696
Kim, Xu, Kastan: Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. in Genes & development 2002
Show all 5 Pubmed References
Human BRCA1 Primary Antibody for IHC - ABIN965694
Arlt, Xu, Durkin, Casper, Kastan, Glover: BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. in Molecular and cellular biology 2004
Show all 5 Pubmed References
Human Monoclonal BRCA1 Primary Antibody for CyTOF, FACS - ABIN152030
Okada, Ouchi: Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. in The Journal of biological chemistry 2003
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody for ICC, FACS - ABIN152032
Martin, Nahas, Tunuguntla, Fike, Gatti: Assessing 'radiosensitivity' with kinetic profiles of γ-H2AX, 53BP1 and BRCA1 foci. in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011
Show all 4 Pubmed References
Polyclonal BRCA1 Primary Antibody for IF - ABIN4948304
Scully, Livingston: In search of the tumour-suppressor functions of BRCA1 and BRCA2. in Nature 2000
Show all 3 Pubmed References
Human Monoclonal BRCA1 Primary Antibody for ChIP, ICC - ABIN151868
Li, Ting, Zheng, Chen, Ziv, Shiloh, Lee, Lee: Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. in Nature 2000
Show all 3 Pubmed References
Human Polyclonal BRCA1 Primary Antibody for IP, PLA - ABIN151492
Rusin, Zajkowicz, Butkiewicz: Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. in Mechanisms of ageing and development 2009
Show all 2 Pubmed References
The authors assessed whether BRCA1 promoter hypermethylation like mutation was associated with increased survival or increased sensitivity to platinum chemotherapy. However the results showed that neither outcomes were met
Data show that breast cancer BRCA1 carriers have distinctive tumour features as compared to BRCA2 carriers and non-carriers. The majority of BRCA1 carriers were diagnosed with tumour size >20 mm, poor differentiation tumour and negative oestrogen and progesterone hormonal receptors.
These results reveal two distinct fork restart pathways, which are antagonistically controlled by 53BP1 and BRCA1 in a double-strand DNA break repair-independent manner.
loss of BRCA1 function results in an increase in UBE2C (show UBE2C Antibodies) expression and chemical resistance to doxorubicin in breast cancer cells.
We describe twenty-nine novel BRCA1 and BRCA2 (show BRCA2 Antibodies) variants detected in Italian individuals suffering from hereditary breast and ovarian cancer syndrome (HBOC).
The work-flow represents a robust and easy-to-use method for full BRCA1/2 screening, which can be easily implemented in routine diagnostic testing and adapted to genes other than BRCA1/2.
Statistically significant correlations were identified between breast cancer and 3 not described previously single nucleotide polymorphisms of homologous recombination repair genes BRCA1 and BRCA2 (show BRCA2 Antibodies): rs59004709, rs4986852 and rs1799950.
a functional-inherited variation in BRCA1 were significantly associated with PFS of TNBC. Our findings may potentially have several clinical implications. For example, the BRCA1 rs799917 genotypes may act as prognostic tools in clinic management of TNBC, especially in patients receiving radiotherapy.
BRCA1 is actively recruited to the alternative lengthening of telomeres that are experiencing replication stress and that the recruitment of BRCA1 to these damaged telomeres is interdependent and is regulated by both ATR (show ANTXR1 Antibodies) and Chk1 (show CHEK1 Antibodies).
results further highlight the antagonistic relationship between 53BP1 and BRCA1, and place Nup153 and Nup50 in a molecular pathway that regulates 53BP1 function by counteracting BRCA1-mediated events.
Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.
The gene-specific SNP marker analysis showed a significant association of BRCA1 C28300A with milk somatic cell scores.
In general, OC use, childbearing and breastfeeding do not differ between BRCA1/2 carriers and non-carriers with ovarian cancer. However, the effects of tubal ligation may differ between BRCA1 carriers and non-carriers.
Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents.These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress.
Consensus-based recombinant adeno-associated virus-BRCA1 knock out virus vectors failed to induce BRCA1 knockout in Gottingen fibroblasts.
Data indicate the importance of breast cancer 1 protein (BRCA1)/breast cancer 2 protein (BRCA2 (show BRCA2 Antibodies)) function in cranial neural crest cells (CNCCs) during craniofacial skeletal formation.
ATM (show ATM Antibodies) has a role in homology-directed repair (HDR (show GATA3 Antibodies)) independent of the BRCA1-53BP1 (show TP53BP1 Antibodies) antagonism; its HDR (show GATA3 Antibodies) function can become critical in certain contexts
BRCA1, but not BRCA2, suppresses the formation of tandem duplications at a site-specific chromosomal replication fork barrier imposed by the binding of Tus proteins to an array of Ter sites. BRCA1 has no equivalent role at chromosomal double-stranded DNA breaks, indicating that tandem duplications form specifically at stalled forks.
Loss of p16INK4 protein (p16) transforms breast cancer 1 (Brca1)-deficient mammary epithelial cell (MEC (show CCL28 Antibodies)) and induces mammary tumors.
Brca1 is necessary for hematopoietic stem cells maintenance and normal hematopoiesis and that distinct mutations lead to different degrees of hematopoietic dysfunction.
TGFbeta (show TGFB1 Antibodies) stabilized the abundance of BRCA1 by reducing the abundance of microRNA-182 (miR (show MLXIP Antibodies)-182). Ectopic expression of BRCA1 or antagonism of miR (show MLXIP Antibodies)-182 in cultured TGFbeta (show TGFB1 Antibodies)-deficient mammary epithelial cells restored luminal lineage commitment.
BRCA1 inactivation can increase expression of miR (show MLXIP Antibodies)-155, contributing to cardiac hypertrophy. And Rev produces their beneficial effects partially by down-regulating miR (show MLXIP Antibodies)-155 expression, which might be a novel strategy for treatment of cardiac hypertrophy.
both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells express a new gene domain-less (RING-less) BRCA1 protein that mediated resistance to homologous recombination deficient-targeted therapies
Genomic instability can be rescued by deletion of Trp53bp1 (show TP53BP1 Antibodies), encoding the DNA damage response factor 53BP1 (show TP53BP1 Antibodies); mice expressing RING-less BRCA1 do not show an increased susceptibility to tumors in the absence of 53BP1 (show TP53BP1 Antibodies); Genomic instability in cells expressing RING-less BRCA1 correlates with loss of BARD1 (show BARD1 Antibodies) and a defect in restart of replication forks after hydroxyurea treatment
the aberrant proliferative capacity of Brca1(-/-) luminal progenitor cells is linked to the replication-associated DNA damage response, where proliferation of mammary progenitors is perpetuated by damage-induced, autologous NF-kappaB (show NFKB1 Antibodies) signaling.
MRN (Mre11 (show MRE11A Antibodies), Rad50 (show RAD50 Antibodies), and Nbs1 (show NLRP2 Antibodies)) complex, CtIP (show RBBP8 Antibodies), and BRCA1 are required for both the removal of Top2 (show TOP2 Antibodies)-DNA adducts and the subsequent resection of Top2 (show TOP2 Antibodies)-adducted DSB ends.
BRCA1-dependent helicase (show DNA2 Antibodies) unloading is a critical, early event in DNA interstrand crosslink repair.
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.
BRCA1/BRCA2-containing complex, subunit 1
, RING finger protein 53
, breast and ovarian cancer susceptibility protein 1
, breast and ovarian cancer sususceptibility protein 1
, breast cancer type 1 susceptibility protein
, protein phosphatase 1, regulatory subunit 53
, BRCA1 homologue
, breast cancer type 1 susceptibility protein homolog
, breast cancer 1, early onset
, BRCA1 homolog
, breast and ovarian cancer susceptibility protein
, breast cancer associated 1